PET in genitourinary tract cancers

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 51, Issue 3, 2007, Pages 260-271

  Fanti, S ^a   Manni, C ^a   Ambrosini, V ^a   Gross, M D ^b   Rubello, D ^c   Farsad, M ^a  

^a Nuclear Medicine   (Italy)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c S MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Neoplasms; Nuclear medicine; Tomography, emission computed; Urogenital system

Indexed keywords

ACETIC ACID C 11; ANDROSTANOLONE F 18; ANTIANDROGEN; ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CHOLINE C 11; CHOLINE F 18; FLUORINE 18; FLUOROACETIC ACID F 18; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLCHOLINE F 18; FLUOROMETHYL DIMETHYL HYDROXYETHYLAMMONIUM F 18; METHIONINE C 11; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; TESTOSTERONE F 18; UNCLASSIFIED DRUG;

BLADDER CANCER; CANCER LOCALIZATION; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG METABOLISM; DRUG RESPONSE; DRUG URINE LEVEL; ECHOGRAPHY; GYNECOLOGIC CANCER; HUMAN; INTERMETHOD COMPARISON; KIDNEY CANCER; LYMPH NODE METASTASIS; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; TESTIS CANCER; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER; UTERUS CANCER;

HUMANS; IMAGE ENHANCEMENT; POSITRON-EMISSION TOMOGRAPHY; UROGENITAL NEOPLASMS;

EID: 34547585205     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Baak JP, Wisse-Brekelmans EC, Langley FA, Talerman A, Delemarre JF. Morphometric data to FIGO stage and histological type and grade for prognosis of ovarian tumours. J Clin Pathol 1986;39:1340-6.
3. Wong TZ, Jones EL, Coleman RE. Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. Mol Imaging Biol 2004;6:55-62.
4. Sironi S, Buda A, Picchio M, Perego P, Moreni R, Pellegrino A et al. Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology 2006; 238:272-9.
5. Rob JW, Seo SS, Lee S, Kang KW, Kim SK, Sim JS et al. Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: a prospective surgicopathologic correlation study. Eur J Cancer 2005;41:2086-92.
6. 18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer 2005;104:2484-91.
7. Choi HJ, Roh JW, Sec, SS, Lee S, Kim JY, Kim SK et al. Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: a prospective study. Cancer 2006;106:914-22.
8. Yen TC, Lai CH, Ma SY, Huang KG, Huang HJ, Hong JH et al. Comparative benefits and limitations of (18)F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer. Eur J Nucl Med Mol Imaging 2006;33:1399-407.
9. Chung HH, Jo H, Kang WJ, Kim JW, Park NH, Song YS et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2006; [Epub ahead of print].
10. 18F-FDG PET for recurrent cervical cancer. J Nucl Med 2004;45:1632-9.
11. 18F- FDG PET in the management of endometrial cancer. Eur J Nucl Med Mol Imaging 2006;33:36-44.
12. Murakami M, Tsukada H, Shida M, Watanabe M, Maeda H, Koido S et al. Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas. Int J Gynecol Cancer 2006;16:854-60.
13. American Cancer Society. Cancer facts and figures: 1998. Atlanta, GA: American Cancer Society; 1998.
14. Forstner R, Chen M, Hricak H. Imaging of ovarian cancer. J Magn Reson Imaging 1995;5:606-13.
15. Yoshida Y, Kurokawa T, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y et al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR Am J Roentgenol 2004;182:227-33.
16. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. j Clin Oncol 2005;23:7445-53. Erratum in: J Clin Oncol 2005;23:9445.
17. Menzel C, Dobert N, Hamscho N, Zaplatnikov K, Vasvatekis S, Matic V et al. The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer. Strahlenther Onkol 2004;180:497-501.
18. Nanni C, Rubello D, Farsad M, De laco P, Sansovini M, Erba P et al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol 2005;31:792-7.
19. 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol 2005;10:177-81.
20. Torizuka T, Kanno T, Futatsubashi M, Okada H, Yoshikawa E, Nakamura F et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. J Nucl Med 2003;44:1051-6.
21. Hain SF, Maisey MN. Positron emission tomography for urological tumours. BJU Int 2003;92:159-64.
22. Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Harper PG, Huddart RA. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 2000;83:863-9.
23. Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography of residual radiological abnormalities in postchemotherapy germ cell tumour patients. J Clin Oncol 1996;14:1637-41.
24. Cremerius U, Effert PJ, Adam G, Sabri O, Zimmy M, Wagenknecht G et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med 1998;39:815-22.
25. Motzer R, Bosl G, Heelan R, Fair W, Whitmore W, Sogani P et al. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 1987;5:1064-70.
26. Puc HS, Heelan R, Mazumdar M, Herr H, Scheinfeld J, Vlamis V et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1996;14:454-60.
27. Horwich A, Paluchowska B, Norman A, Huddart R, Nicholls J, Fisher C et al. Residual mass following chemotherapy of seminoma. Ann Oncol 1997;8:37-40.
28. De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22:1034-9.
29. Bokemeyer C, Kollmannsberger C, Oechsle K, Dohmen BM Pfannenberg A, Claussen CD et al. Early prediction of treatmeni response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET. Br J Cancer 2002;86:506-11.
30. Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Partridge SE, Huddart RA. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 2000; 27:590-4.
31. Cremerius U, Wildberger JE, Borchers H, Zimny M, Jakse G, Gunther RW et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients. Urology 1999;54:900-4.
32. Lassen U, Daugaard G, Eigtved A, Hojgaard L, Damgaard K, Rorth M. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging 2003;30:396-402.
33. Kuo PH, Cooper DL, Cheng DW. Recurrence of lymphoma presenting as asymmetrically increased testicular activity on FDG-PET/CT. Semin Nucl Med 2006;36:105-7.
34. Weng LJ, Schoder H. Melanoma metastasis to the testis demonstrated with FDG PET/CT. Clin Nucl Med 2004;29:811-2.
35. Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F et al. Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 2003;30:1236-45.
36. Kocher F, Geimmel S, Hauptmann R, Reske S. Preoperative lymph node staging in patients with kidney and urinary bladder neoplasm. J Nucl Med 1994;35:223P.
37. Bachor R, Kotzerke J, Gottfried HW, Brandle E, Reske SN, Hautmann R. Positron emission tomography in diagnosis of renal cell carcinoma. Urologe A 1996;35:146-50
38. Goldberg MA, Mayo-Smith WW, Papanicolaou N, Fischman AJ, Lee MJ. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 1997;52:510-5.
39. Montavers F, Grahek D, Kerrou K, Younsi N, Doublet JD, Gattegno B et al. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera. J Nucl Med 2000;41:78-84.
40. Ramdave S, Thomas GW, Berlangieri SU, Bolton DM, Davis I, Danguy HT. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001;166:825-30.
41. Kang DE, White RL Jr, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004;171:1806-9.
42. Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003;21:3995-4000.
43. Ficarra V, Righetti R, Pilloni S, D'amico A, Maffei N, Novella G et al. Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases. Eur Urol 2002;41:190-8.
44. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000;163:1090-5; quiz 1295.
45. Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship. Br J Urol Int 2006;97:916-22.
46. Shreve P, Chiao PC, Humes HD, Schwaiger M, Gross MD. Carbon-11-acetate PET imaging in renal disease. J Nucl Med 1995;36:1595-601.
47. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999;36:31-5.
48. Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18-fluorine-labeled deoxyglucose. J Urol 1996;155:994-8.
49. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001;61:3599-603.
50. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990-5.
51. 18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003;169:1337-40.
52. Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000;27:1415-9.
53. 11C-choline positron emission tomography. Eur Urol 2002;42:18-23.
54. 11C-choline PET. J Nucl Med 2003;44:331-5.
55. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44:32-8; discussion 38-9.
56. Roivainen A, Forsback S, Gronroos T, Lehikoinen P, Kahkonen M, Sutinen E et al. Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography. Eur J Nucl Med 2000;27:25-32.
57. Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004;31:317-24.
58. Hara T, Kosaka N, Kishi H. Development of (18)F-?uoroethyl-choline for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002;43:187-99.
59. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001;61:110-7.
60. Shreve P, Chiao PC, Humes HD, Schwaiger M, Gross MD. Carbon-11-acetate PET imaging in renal disease. J Nucl Med 1995;36:1595-601.
61. Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2002;29:1380-4.
62. 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003;30:607-11.
63. Yoshimoto M, Waki A, Yonekura Y, Sadato N, Murata T, Omata N et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 2001;28:117-22.
64. 11Clacetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging 2002;29:1492-5.
65. Buonasera TA, O'Neil JP, Xu M, Dobkin JA, Cutler DB, Lich LL et al. Preclinical evaluation of ?uorine-18-labeled androgen receptor ligands in baboons. J Nucl Med 1996;37:1009-15.
66. 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004;45:366-73.
67. Nilsson S, Kalkner K, Ginman C et al. C-11methionine positron emission tomography in the management of prostatic carcinoma. Antibody Immunconj Radiopharm 1995;8:23.
68. Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005;46:1642-9.
69. D'Amico AV, Whittington R, Schnall M, Malkovicz SB, Thomaszewski JE, Schultz D et al. The impact of the inclusion of endorectal coil magnetic resonance imaging in a multi-variate analysis to predict clinically unsuspected extraprostatic cancer. Cancer 1995;75:2368-72.
70. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002;43:181-6.
71. Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004;231:379-85.
72. Cher ML, Bianco FJ Jr, Lam JS, Davis LP, Grignon DJ, Sakr WA et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160:1387-91.
73. Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vande Berg B, Lecouvet FE. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate 2005;65:178-87.
74. Shoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34:274-92.
75. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003;44:549-55.
76. 11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003;42:25-30.
77. 11C-Choline PET for restaging surgically treated prostate cancer patients: relation with PSA levels and anti-androgenic therapy. Q J Nucl Med Mol Imaging 2006;50:34-5.
78. Oyama N, Akino H, Suzuki Y, Kanamaru H, Ishida H, Tanase K et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun 2001;22:963-9.
79. 11C-choline positron emission tomography/ computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006;176:954-60; discussion 960. Erratum in: J Urol 2006;176(6 Pt 1): 2749.
80. 11C-chohne PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med 2006;47:938-44.
81. 11C-choline positron emission tomography/ computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol 2006; 176:940-4; discussion 944.
82. Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 2005;32:1412-7.